CardioFocus, a company out of Marlborough, Massachusetts, is releasing in the U.S. its HeartLight endoscopic ablation system for treating paroxysmal atrial fibrillation. Having received FDA approval back in April, the company is starting rolling out the device with first post approval use at Mount Sinai Hospital in New York City.
Unlike other ablation catheters, no X-rays or EP cardiac mapping is necessary when targeting tissue. This is thanks to a compliant transparent balloon and built-in illumination that lets the physician see the area around the ablation target. A laser light delivered via an optical fiber is used to energize and kill the tissue.
“Following approval from the U.S. FDA, we are pleased to now commercially offer HeartLight for paroxysmal AF patients in the U.S. market,” said Paul LaViolette, CardioFocus Executive Chairman in a statement. “HeartLight has already been used to treat more than 3,700 patients worldwide, and building on the first commercial U.S. procedure at Mount Sinai, we will continue to scale up installations at electrophysiology labs across the country to treat patients in need. Our focused and selective launch, which enables us to move forward strategically and work closely with hand-picked physicians and sites, is proceeding as planned. We continue to receive excellent feedback from interested physicians.”
Here’s a video explaining how the HeartLight works:
Flashback: CardioFocus HeartLight Ablation System with Direct Visual Guidance FDA Approved…
Link: CardioFocus homepage…
Via: CardioFocus…